Peer-reviewed veterinary case report
Miltefosine vs meglumine antimoniate for treating dog leishmaniosis
By Mateo, Marta et al.·Published in Parasitology research·2009·Dpto. Sanidad Animal, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
- Species:
- dog
Plain-English summary
A group of dogs with leishmaniosis, a disease caused by parasites, were treated with either an oral medication called miltefosine or an injectable drug called meglumine antimoniate for 28 days. Both treatments significantly improved the dogs' health, with about 90% of the dogs showing no signs of the disease in follow-up tests. While some dogs experienced mild stomach issues from the medications, most tolerated the treatments well. Overall, miltefosine was found to be a safe and effective option for treating leishmaniosis in dogs.
People also search for: dog leishmaniosis treatment · miltefosine for dogs · meglumine antimoniate side effects
Abstract
The aim of this study was to compare the efficacy and safety of oral administration of miltefosine (Milteforan) at 2 mg/kg/day for 28 days (Group M; n = 60) with a subcutaneous administration of meglumine antimoniate (Glucantime) at 50 mg/kg/12 h or at 100 mg/kg/day for 28 days (Group G; n = 59) in the treatment of canine leishmaniosis in dogs. Out of 119 dogs included in the study, 90 could be used for efficacy assessment and 112 for safety assessment. Treated dogs were followed up for 6 weeks, with re-checks every 14 days. The mean total clinical scores significantly decreased throughout the study in both treatment groups. The evolution of parasitological results after treatment (D42) shows a high percentage of dogs with negative bone marrow smears, 90% and 91.3% in groups M and G respectively, and did not significantly differ between groups (p = 0.8066). Out of the 112 dogs used for the safety assessment, only 26 dogs (23.2%) presented product-related adverse events concerning the gastrointestinal tract. These results showed that miltefosine at 2 mg/kg once daily can be safely used over a 28-day period in the treatment of canine leishmaniosis and provides both a steadily increasing improvement of the clinical signs and a good leishmanicidal efficacy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19238439/